Physician profile
Daniel Seung Han
NPI 1952712812
$4,021.90
in general payments reported to CMS, 2019-2025
32 companies · $1,651 in 2025
The $1,651 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31.99 · 2021: $158 · 2022: $58.23 · 2023: $747 · 2024: $1,375 · 2025: $1,651.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,773.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,773.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $596.27 | 2022-2025 | |
| Lilly USA, LLC | $571.57 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $500.37 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $377.27 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $328.36 | 2024-2025 | Farxiga, Airsupra |
| Novartis Pharmaceuticals Corporation | $298.56 | 2023-2025 | |
| Amgen INC. | $254.18 | 2023-2025 | Repatha, Otezla, Evenity |
| Phathom Pharmaceuticals, INC. | $172.90 | 2024-2025 | Voquezna |
| Abbott Laboratories | $113.25 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Sk Life Science, INC. | $85.64 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $75.15 | 2023-2024 | Austedo Xr, Ajovy |
| E.R. Squibb & Sons, L.L.C. | $74.75 | 2024-2025 | Eliquis |
| Exact Sciences Corporation | $69.93 | 2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $64.66 | 2023 | Rexulti |
| Biogen, INC. | $62.83 | 2024 | Skyclarys |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $34.51 | 2025 | Dyanavel Xr |
| Noven Therapeutics, LLC | $32.38 | 2023-2024 | Xelstrym |
| Kci USA, INC. | $31.99 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.78 | 2023-2025 | |
| Boston Scientific Corporation | $28.38 | 2022 | |
| Gilead Sciences, INC. | $25.92 | 2023 | |
| Xeris Pharmaceuticals, INC. | $24.35 | 2023 | Gvoke Hypopen |
| Axsome Therapeutics, INC. | $21.19 | 2025 | Symbravo |
| Scpharmaceuticals INC. | $19.96 | 2025 | |
| Ardelyx, INC. | $18.20 | 2024 | Ibsrela |
| Vertex Pharmaceuticals Incorporated | $18.00 | 2025 | |
| Merck Sharp & Dohme LLC | $17.35 | 2023 | Verquvo, Belsomra |
| Idorsia Pharmaceuticals US INC | $16.64 | 2023 | Quviviq |
| Dexcom, INC. | $16.25 | 2025 | Dexcom G6 Transmitter |
| Antares Pharma, INC. | $15.02 | 2023 | Tlando, Xyosted, Nocdurna |
| Janssen Pharmaceuticals, INC | $13.20 | 2022 | |
| Southern Implants North America INC | $11.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Han listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.